ose 2101,tedopi
ose immunotherapeutics
['atalante-1', 'tedopi']
four poster presentations at 2022 asco annual meeting - atalante-1 phase 3 trial beyond checkpoint inhibitor neoepitope specific immunotherapy tedopi shows significant patient-reported outcomes versus chemotherapypositive interim results in phase 2 tri... 
CEO Of Digital Media Online